Compare Amgen, Inc. (AMGN) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs H2O America — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while H2O America trades at $62.13 (market cap $2.57B). The key difference: Amgen, Inc. is far larger — about 76.3× H2O America's market cap, and H2O America pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| AMGN | HTO | |
|---|---|---|
Market Cap | $196.12B | $2.57B |
Sector | Health | Technology |
52-Week High | $388.16 | $62.42 |
52-Week Low | $271.18 | $44.44 |
Enterprise Value | $241.41B | $4.29B |
Dividend Yield | 2.77% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $360.45, down 0.81% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly EPS beats. Revenue grew to $36.75B in 2025 with a net income margin of 20.96%, though high debt levels and recent regulatory challenges for Tavneos in Europe present headwinds. Analyst sentiment is positive with 57.9% buy ratings and a consensus price target of $351.29.
The outlook for AMGN is cautiously optimistic, supported by earnings momentum and a diversified product portfolio, but investors face risks from patent expirations, competitive biosimilar pressures, and regulatory setbacks. The stock's current price near consensus target suggests limited near-term upside, requiring careful monitoring of pipeline developments and debt management.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
